Belarus. Pharmaceutical Market Overview 2013
The pharmaceutical market is of strategic importance for the Republic of Belarus, which is reflected in the functioning of the industry. So, this market is high-yield, especially in the retail segment. However, it has its own specific features such as price controls, which is reflected not only in the pharmacy market, but also in producers.
The program of import substitution on the pharmaceutical industry largely depends on the raw materials and APIs which are not produced in Belarus for the production of drugs (according to the experts of the Department of the pharmaceutical industry, the share of imports in the production of certain types of products reaches 70-80%). For this reason, in 2011 because of restrictions on the foreign exchange market, Belarusian pharmaceutical manufacturers were in a difficult situation. However, in 2012, is a restoration of the industry after the crisis. And in 2013, the industry came back to previous growth rates.
Belarusian pharmaceutical companies produce more than 1100 different products, while in total Belarus has registered about 5500 names. Local pharmaceutical companies produce about 30% of the world available marketing products by nomenclature and INNs.
In 2013, Belarus produced more than 420 million units (+ 7.4% YoY) of pharmaceutical products in hitting the total value of about USD 480 million (+ 50% YoY). Average annual growth rate in value terms over the last 5 years was 30% (moreover, in some years, the increase was more than 50%). Average annual growth rate for the period from 2009 to 2013 in volumes was 4.4%.
In total, pharmaceutical production in Belarus carry out more than 25 business entities, including 2 fully state owned and 3 state-owned enterprises with the state share over 50%.
In 2013, pharmaceutical exports increased by 11% to $ 163 million. During the 2009-2013 period exports in value terms increased by 1.9 times, and the average annual growth rate for the same period was 17%.
Drug consumption per capita in Belarus in 2013 amounted to USD 113 (+ 31.5% compared with 2012). The level of drug consumption in Belarus is the second after the Russian Federation indicator and the highest compared to other countries.
Largest Belarusian pharmaceutical companies - RUE "Belmedpreparaty", JSC "Borisov Medical Preparations Plant" ("BZMP"), JV "Farmland" JV "Lekpharm" UP Minskinterkaps. Their combined market share is 21.3% (or USD 227,7 million). In 2013, sales attributable to top-5 national producers, increased by 44.4%.
Source: Uniter
Leave a Comment